The Tradr 2X Long ALAB Daily ETF, launched in August 2025 and managed by Tradr, a brand of AXS Investments, seeks daily investment results of two times the daily performance of Astera Labs common shares. Astera Labs designs semiconductor-based connectivity solutions—including PCIe and CXL retimers, fabric switches, and smart cable modules—for cloud and AI data-center infrastructure.
Unlike a diversified sector fund, LABX concentrates its exposure in a single underlying stock using derivatives and swap agreements rather than a broad basket of securities. The fund reports only a handful of portfolio positions, with gross exposure exceeding 100% of net assets to achieve its 2x objective (domestic equity exposure is approximately 113.6% of assets, offset by negative cash). This structure is materially different from a conventional index ETF and produces amplified daily moves in both directions. I also checked this using Tickeron’s AI Screener to see how the fund compares to other leveraged products in the sector.
The fund carries an expense ratio of approximately 1.30%, roughly $80 million in assets under management (AUM), and is classified as non-diversified. Because it rebalances exposure daily, its returns over periods longer than a single trading day will diverge from two times Astera Labs' cumulative return—a core risk embedded in its design.
Over the last 30 days, LABX advanced approximately 34%, rising from a close near $7.85 to $10.52. The move was far from linear: the fund recorded multiple double-digit percentage swings within the period as Astera Labs shares rallied and then pulled back.
The trailing quarter tells a different story. From a level near $14.81 in mid-July, LABX is down roughly 29% through mid-October despite the recent bounce. This divergence between the 30-day and three-month figures underscores the path-dependence of leveraged daily-reset products—sharp rallies can occur even while a fund remains below prior highs because of volatility decay and the compounding of daily returns.
The 30-day advance was primarily a reflection of strength in ALAB, which gained roughly 20% over the same window, with LABX amplifying that move through its 2x daily leverage. Astera Labs issued third-quarter revenue guidance of approximately $540 million to $560 million, implying sequential growth of roughly 40%, as its Scorpio AI fabric switches moved toward becoming its largest product family and its Aries PCIe 6 retimers delivered record revenue.
Product announcements reinforced sentiment. The company unveiled its Aries 7 PCIe 7 signal-conditioning portfolio and participated in demonstrations—including PCIe-over-optics work with Lumentum and Corning—at an industry summit focused on AI rack-scale connectivity. These developments positioned Astera Labs as a direct beneficiary of hyperscaler spending on AI data centers.
The period also showed the fund's downside sensitivity. Late in the window, Astera Labs shares pulled back after an analyst downgrade citing valuation and broader concerns tied to AI-spending assumptions, with the stock declining roughly 9% in a single session. That reversal produced a correspondingly sharp drop in LABX, illustrating how quickly leveraged single-stock exposure can unwind. From what I see, reviewing these moves with Tickeron’s AI Trend Prediction Engine helped clarify the momentum shifts.
Across the trailing three months, LABX's decline reflects two reinforcing forces. First, Astera Labs shares themselves corrected from their late-summer highs, weighed down by valuation sensitivity in high-multiple connectivity names and periodic investor unease about the durability of AI capital spending. Second, the daily-reset 2x structure suffered from volatility decay during a period of unusually wide swings, which erodes value even when the underlying stock does not move decisively in one direction.
Competitive dynamics also played a role. Investors weighed Astera Labs against established connectivity and networking suppliers such as MRVL, while rotating among AI-infrastructure names as sentiment around data-center buildouts shifted. These structural and positioning factors, more than any single news event, shaped the fund's broader three-month trend.
Several factors are likely to shape LABX over the coming months. Astera Labs' quarterly earnings report and its commentary on the Scorpio ramp, gross-margin mix, and customer concentration will be pivotal, given how sensitive the shares are to execution and guidance. Broader AI-infrastructure capital spending by hyperscalers, along with the pace of PCIe 6 and PCIe 7 adoption, will influence demand for the company's connectivity products.
Macroeconomic conditions also matter. Interest-rate expectations and inflation trends affect the valuation of high-multiple growth and semiconductor names, while any reassessment of AI-spending assumptions can trigger rapid repricing. Investors should additionally monitor the structural risks unique to LABX itself: daily-reset leverage, volatility decay, rebalancing costs, and the liquidity of a relatively small single-stock fund. These characteristics make LABX appropriate primarily for experienced traders with a short-term horizon and active risk management, rather than long-term investors seeking diversified exposure. I'm watching this closely as earnings season approaches.
In my own analysis of products like LABX, Tickeron’s AI Screener has become a useful part of the workflow. It allows quick scans across technical indicators, fundamentals, volatility metrics, and industry filters to identify comparable leveraged instruments or monitor momentum changes. The platform helps surface ideas that align with specific performance characteristics, which can be especially helpful when evaluating single-stock ETFs amid sector swings. This kind of tool supports more efficient research without replacing careful review of the underlying risks.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
My name is Jimmy, and I’m a financial analyst focused on identifying compelling opportunities across the ETF market. Each day, I analyze hundreds of ETFs to uncover potential trading and investment opportunities using a broad range of market factors. For short-term trading, I rely heavily on technical analysis, including price channels, momentum indicators, support and resistance levels, trend patterns, and other market signals. At the same time, I dedicate significant attention to evaluating ETFs from a long-term investment perspective. My objective is to build a well-balanced ETF portfolio that combines core investment holdings with more tactical and speculative positions. The goal is to create a portfolio that can participate effectively in market rallies while also remaining resilient during periods of volatility and market corrections.
The 10-day RSI Oscillator for LABX moved out of overbought territory on October 07, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 8 instances where the indicator moved out of the overbought zone. In 8 of the 8 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
The Momentum Indicator moved below the 0 level on October 08, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on LABX as a result. In 20 of 20 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for LABX turned negative on October 09, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 11 similar instances when the indicator turned negative. In 11 of the 11 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
LABX moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LABX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The 10-day moving average for LABX crossed bullishly above the 50-day moving average on September 25, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 3 of 3 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Following a +22.60% 3-day Advance, the price is estimated to grow further. Considering data from situations where LABX advanced for three days, in 69 of 72 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.
LABX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 55 of 60 cases where LABX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
Category Trading